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Objectives: Fructose-1,6-diphosphate is a glycolytic intermediate that has
been shown experimentally to cross the cell membrane and lead to
increased glycolytic flux. Because glycolysis is an important energy source
for myocardium during early reperfusion, we sought to determine the
effects of fructose-1,6-diphosphate on recovery of postischemic contractile
function. Methods: Langendorff-perfused rabbit hearts were infused with
fructose-1,6-diphosphate (5 and 10 mmol/L, n 5 5 per group) in a
nonischemic model. In a second group of hearts subjected to 35 minutes of
ischemia at 37° C followed by reperfusion (n 5 6 per group), a 5 mmol/L
concentration of fructose-1,6-diphosphate was infused during the first 30
minutes of reperfusion. We measured contractile function, glucose uptake,
lactate production, and adenosine triphosphate and phosphocreatine levels
by phosphorus 31–nuclear magnetic resonance spectroscopy. Results: In the
nonischemic hearts, fructose-1,6-diphosphate resulted in a dose-dependent
increase in glucose uptake, adenosine triphosphate, phosphocreatine, and
inorganic phosphate levels. During the infusion of fructose-1,6-diphos-
phate, developed pressure and extracellular calcium levels decreased.
Developed pressure was restored to near control values by normalizing
extracellular calcium. In the ischemia/reperfusion model, after 60 minutes
of reperfusion the hearts that received fructose-1,6-diphosphate during the
first 30 minutes of reperfusion had higher developed pressures (83 6 2 vs
70 6 4 mm Hg, p < 0.05), lower diastolic pressures (7 6 1 vs 12 6 2 mm
Hg, p < 0.05), and higher phosphocreatine levels than control untreated
hearts. Glucose uptake was also greater after ischemia in the hearts treated
with fructose-1,6-diphosphate. Conclusions: We conclude that fructose-1,6-
diphosphate, when given during early reperfusion, significantly improves
recovery of both diastolic and systolic function in association with in-
creased glucose uptake and higher phosphocreatine levels during reperfu-
sion. (J Thorac Cardiovasc Surg 1998;116:335-43)
Fructose 1,6-diphosphate (FDP) is a glycolyticintermediate that has been proposed as an effec-
tive drug to improve myocardial function in chronic
congestive heart failure1 and in the treatment of
patients in the early phase of acute myocardial
infarction.2 The exact mechanism(s) of action of
FDP in these two clinical conditions is not known.
However, two major effects on myocardium have
been proposed to explain the ameliorative effects of
FDP that may significantly affect reperfused myo-
cardium: (1) the positive effects of FDP on glycolysis
and the energetic state of the heart and (2) the
ability of FDP to bind free calcium.
Although FDP is a polar molecule because of its
phosphate moieties, there is now good evidence that
it can cross the cell membrane in a dose-dependent
manner. Hardin and Roberts,3 using carbon 13–
nuclear magnetic resonance (NMR), demonstrated
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that exogenous 13C-labeled FDP can enter the cell
and, during hypoxia, can lead to the generation of
13C-lactate. The ability of FDP to increase myocar-
dial high-energy phosphates has been ascribed to
several potential mechanisms. Markov and associ-
ates4 have shown that FDP can restore the de-
pressed glycolytic activity in ischemic myocardium
by regulatory effects on the glycolytic pathway and
also as a substrate for this pathway. Other investi-
gators have also suggested that FDP can enter the
cytosol in sufficient quantities to function as a direct
substrate for glycolysis.5-7
FDP has also been shown to lower the free Ca21
concentration in crystalloid solutions such as Krebs-
Fig. 1. a, Ionized calcium concentration in a solution of
Krebs buffer alone (pre), Krebs 1 a 5 mmol/L concentra-
tion of FDP (1FDP 5mM), and Krebs 1 FDP 1 increas-
ing concentrations of total calcium achieved by the addi-
tion of calcium chloride in vitro (1CaCl2[mM]). b,
Developed pressure (expressed as percent of pre-FDP
infusion value) in a nonischemic heart perfused with
Krebs 1 a 5 mmol/L concentration of FDP (value at left)
and Krebs 1 FDP 1 increasing ionized calcium concen-
trations in the perfusate (achieved by the addition of
calcium chloride). All values are mean 6 standard error,
n 5 5.
Fig. 2. Effects of FDP infusion on developed pressure (a)
and MVO2 (b) followed by Krebs buffer perfusion (wash)
in a nonischemic heart model. Developed pressure is
expressed as percent of pretreatment (pre) values. All
values are mean 6 standard error. *p , 0.05 compared
with pre-FDP values; n 5 5 per group.
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Henseleit bicarbonate buffer.7 In an isolated rat
heart model, FDP was found to chelate extracellular
calcium in association with decreased contractile
forces. However, the precise relationship between
FDP concentration, extracellular ionized calcium
levels, and myocardial contractile function has not
been fully clarified.
Because glycolysis and extracellular calcium con-
centration during early reperfusion have been
shown to play an important role in recovery of
myocardial function, the goals of this study were to
determine the effects of FDP on myocardial recov-
ery of contractile function and high-energy phos-
phates in an isolated rabbit heart model. To further
clarify the mechanism of action of FDP on the heart,
we studied the effects of FDP on high-energy phos-
phates, contractile function, and extracellular cal-
cium in a nonischemic isolated crystalloid-perfused
rabbit heart preparation.
Materials and methods
Chemicals and reagents. Chemicals for the Krebs
buffer solutions were obtained from Sigma Chemical Co.
(St. Louis, Mo.). FDP was obtained courtesy of Biomedica
Foscama (Rome, Italy) and from Sigma Chemical Co.
Nonischemic model
Animal preparation and experimental protocol. New
Zealand White rabbits weighing 3 to 4 kg were anesthe-
tized with intravenous ketamine hydrochloride (60 mg/
kg). The heart was isolated and perfused via an aortic
cannula in the Langendorff manner. The perfusate used
was Krebs-Henseleit buffer, which contained glucose, 11
mmol/L, and insulin, 10 m/L, and was equilibrated with
95% oxygen and 5% carbon dioxide and maintained at
37° C with the use of water-jacketed glassware. The
inferior and superior venae cavae and pulmonary veins
were sutured closed. The pulmonary artery was cannu-
lated, and samples were taken anaerobically. Left ventric-
ular pressure was monitored by a pressure transducer
connected to a latex balloon inserted in the left ventricle
via the left atrium. In the nonischemic heart model, the
hearts were perfused for a 30-minute equilibration period,
followed by a 15-minute period of FDP infusion, followed
by a washout period with standard Krebs buffer.
Ca21 titration protocol. To determine the relationship
between extracellular FDP, free ionized calcium concen-
tration, and myocardial contractile function, we con-
ducted the following experiment. After an initial 30-
minute stabilization period, rabbit hearts that had been
perfused with Krebs-Henseleit solution were infused with
Fig. 3. a, Phosphocreatine; b, inorganic phosphate; c, b-ATP. Concentrations in perfused nonischemic
hearts in response to 5 and 10 mmol/L concentrations FDP measured by 31P-NMR spectroscopy. Values
are expressed as percent change from pre-FDP (pre) levels. All values are mean 6 standard error. *p ,
0.05 compared with pre-FDP values; n 5 5 per group.
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buffer containing a 5 mmol/L concentration of FDP. Free
ionized calcium in the perfusate was measured with a
calcium-sensitive microelectrode (NOVA6, NOVA Med-
ical, Waltham, Mass.), additional calcium (CaCl2, 0.2 to
0.8 mmol/L) was added to the perfusate buffer, and the
final ionized calcium levels were measured. The supple-
mental Ca21 infusion was started 1 minute after the onset
of the FDP infusion and given for 5 minutes, followed by
a 5-minute washout period. Subsequent calcium infusions
were given after the 5-minute washout period. Peak
developed pressure and ionized calcium concentration of
the perfusate were measured at the end of each of the
5-minute calcium infusion periods.
Effects of FDP on high-energy phosphates in the nonisch-
emic heart. Two groups of animals (n 5 5 per group) were
studied. A nonischemic heart model was perfused with
Krebs buffer containing FDP (5 and 10 mmol/L). Myocar-
dial high-energy phosphates were measured by 31P-NMR
spectroscopy. The hearts were perfused in a 40 cm hori-
zontal-bore, 4.7 T Bruker BioSpec NMR spectrometer
(Bruker Instruments, Inc., Billerica, Mass.) operating at a
frequency of 81 MHZ. The perfusion chamber was sur-
rounded by a 3.1 cm diameter, five-turn solenoid coil
tuned to 81 MHz for 31P spectroscopy. Ninety-degree
radiofrequency pulses were applied with a recycle time of
1 second during a period of 2 minutes 40 seconds, for a
total of 148 acquisitions per spectrum. A bulb containing
dimethylene phosphonic acid (DMPA) as an internal 31P
standard was placed within the right ventricle, and the
right atrium was sutured closed. The areas under the
b–adenosine triphosphate (ATP), phosphocreatine (PCr),
inorganic phosphate (Pi), and DMPA peaks were deter-
mined by integration after baseline correction with the
polynomial curve-fitting routine supplied by Bruker In-
struments, Inc. All peaks were normalized to the DMPA
peaks. Krebs buffer containing FDP (5 and 10 mmol/L)
was infused for 15 minutes and the hearts were then
perfused with plain Krebs buffer for a 30-minute washout
period. Developed pressure was monitored continuously
during the experiments. Myocardial oxygen consumption
(MVO2) was measured before FDP infusion, at 3 and 10
minutes of FDP infusion, and after 5 and 20 minutes of
washout in both groups.
Ischemia/reperfusion model
Experimental protocol. For the ischemia/reperfusion ex-
periments, the experimental protocol consisted of a 30-
minute equilibration period followed by 35 minutes of
37° C ischemia induced by aortic clamping, followed by
reperfusion. Left ventricular developed pressure and end-
diastolic pressure were evaluated before ischemia and at
30 and 60 minutes of reperfusion at the same balloon
volume. This duration of ischemia was chosen because we
have found that in this animal preparation it produces a
significant degree of postischemic contractile dysfunction
without the onset of rigor during ischemia. To test for the
onset of rigor, after ischemic arrest (approximately 10 to
12 minutes), we adjusted the left ventricular balloon
volume to generate a resting left ventricular pressure of 2
mm Hg and maintained this pressure until reperfusion.
Onset of rigor was defined as a 5 mm Hg rise in left
ventricular resting pressure. Ischemic rigor was not ob-
served in any of the hearts in these experiments. After
reperfusion, the balloon volume was returned to the
preischemic level for the contractile function measure-
ments.
In the FDP-treated hearts, a stock solution of FDP
adjusted to pH 7.4 with NaOH and Krebs-Henseleit
solution was infused into the aortic cannula at a rate to
yield a final concentration of 5 mmol/L for the first 30
minutes of reperfusion. Reperfusion was then continued
with plain Krebs buffer until the end of the experiment.
Control hearts received only Krebs buffer during the
entire reperfusion period.
Metabolic analysis. MVO2, glucose extraction, and lac-
tate production were assessed before ischemia and at 2.5,
Fig. 4. Developed pressure (a) and end-diastolic pres-
sure (b) in hearts subjected to 30 minutes of ischemia at
37° C followed by 60 minutes of reperfusion. In one group,
a 5 mmol/L concentration of FDP was added to the Krebs
buffer for the initial 30 minutes of reperfusion followed by
30 minutes with Krebs buffer alone. In a second (control)
group, hearts were reperfused with Krebs buffer alone. All
values are mean 6 standard error. *p , 0.05 compared
with control hearts; n 5 6 per group.
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5, 10, 30, 32.5, and 45 minutes of reperfusion. MVO2 was
derived from the difference of oxygen tension between
aortic perfusate and coronary effluent (ABL-3 Acid-Base
Laboratory, Radiometer A/S, Copenhagen, Denmark)
and the coronary flow rate. Glucose extraction was de-
rived from the difference in glucose concentration be-
tween aortic perfusate and coronary effluent, multiplied
by coronary flow, and divided by heart weight. Lactate
released from the heart into the coronary was measured
by enzymatic analysis (lactate-glucose analyzer 2300
STAT, YSI, Yellow Springs, Ohio) and determined by the
calculation of coronary flow times lactate per gram dry
weight.
High-energyphosphatemeasurements. High-energyphos-
phate content was measured in an additional two groups
of animals (n 5 6 per group) subjected to 35 minutes of
normothermic ischemia followed by reperfusion. In one
group a 5 mmol/L concentration of FDP was infused
during the first 30 minutes of reperfusion followed by 15
minutes of washout with plain Krebs buffer. The second
group was subjected to the same ischemic injury but was
reperfused only with Krebs buffer for 45 minutes and
served as the control. Details of the NMR measurements
were the same as described earlier (nonischemic model).
All animals received humane care in compliance with
the “Principles of Laboratory Animal Care” formulated
by the National Society for Medical Research and the
“Guide for the Care and Use of Laboratory Animals”
prepared by the Institute of Laboratory Animal Resources
and published by the National Institutes of Health (NIH
Publication No. 86-23, revised 1985). This protocol was
reviewed and approved by the animal care committee at
Children’s Hospital.
Statistical analysis. Analysis of variance was used for
comparisons of multiple data points between two groups.
When significant differences were detected by analysis of
variance, the unpaired t test was used to assess differences
between individual time points within or between the
groups. All data are expressed as the mean 6 standard
error of the mean.
Results
Nonischemic model
Ca21 titration experiments. Fig. 1, a, depicts the
ionized Ca21 concentration in the perfusate con-
taining a 5 mmol/L concentration of FDP plotted
against the additional CaCl2. The 5 mmol/L FDP
concentration significantly decreased the Ca21 con-
centration of Krebs buffer from 1.19 6 0.03 mg/dl to
0.81 6 0.02 mg/dl (31.8% decrease). With the
additional CaCl2, Ca
21 increased linearly so that an
additional 0.6 mmol/L total calcium concentration
was required to return the ionized calcium concen-
tration to pre-FDP levels. Fig. 1, b, shows, in an
isolated perfused heart model, the change in devel-
oped pressure versus ionized calcium concentration
obtained with the titration scheme described above.
Despite the additional calcium to correct for the
calcium-binding effects of FDP, developed pressure
did not recover fully during the FDP infusion in
these hearts, suggesting that the effect of FDP on
contractile function is only partly related to extra-
cellular calcium levels.
Contractile function and metabolic effects of FDP. The
nonischemic hearts receiving a 5 mmol/L concentration of
FDP had a fall in developed pressure from 69 6 6 mm Hg
to 31 6 5 mm Hg (45% of basal value). In hearts perfused
with a 10 mmol/L concentration of FDP, developed
pressure fell from 75 6 4 mm Hg to 23 6 3 mm Hg (31%
of basal value) with a gradual recovery during the FDP
infusion in both groups (Fig. 2, a). On washout of the
FDP, however, developed pressure immediately recov-
ered to 79 6 8 mm Hg (114% of basal value) and 104 6
4 mm Hg (133% of basal value) in the 5 mmol/L and 10
mol/L FDP groups, respectively, followed by a gradual
return to baseline values. Fig. 2, b, depicts the MVO2
during the FDP infusion and washout period, with a
significant decline during FDP infusion followed by recov-
ery during washout.
High-energy phosphates. The PCr level rose signif-
icantly during the FDP infusion, with the rise being
greater with a 10 mmol/L concentration of FDP
(Fig. 3, a). Similarly, the ATP concentration rose
during FDP infusion, with a greater accumulation in
the hearts receiving a 10 mmol/L concentration of
FDP (Fig. 3, c). Interestingly, the level of Pi also
rose most dramatically during the 10 mmol/L FDP
infusion, with nearly complete recovery by 10 min-
utes of washout (Fig. 3, b). The marked elevation in
Pi occurred despite the rise of high-energy phos-
phates, indicating a net accumulation of phosphate
within the cell during the FDP infusion.
Table I. Diastolic and developed pressure in the ischemia/reperfusion model
Diastolic pressure (mm Hg) Developed pressure (mm Hg)
Pre-
ischemia
Reperfusion
Pre-
ischemia
Reperfusion
30 min 60 min 30 min 60 min
Control 8 6 0.4 19 6 2 17 6 2 92 6 3 74 6 3 77 6 2
FDP (5 mmol/L) 7 6 0.2 14 6 3 9 6 2* 95 6 1 80 6 4 94 6 1*
FDP (5 mmol/L) 1 Ca 8 6 0.5 17 6 2 12 6 1* 96 6 1 81 6 3 90 6 1*
*p , 0.05 versus control; n 5 4 per group.
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Ischemia/reperfusion model
Contractile function. Left ventricular resting pres-
sure measured at constant balloon volume did not
change during the 35-minute ischemic period in any
of the hearts studied, indicating that this degree of
ischemia did not lead to ischemic contracture.
After 35 minutes of normothermic ischemia and
30 minutes of reperfusion, left ventricular developed
pressure decreased from 88 6 3 mm Hg to 70 6 4
mm Hg (78% of preischemic level) in control un-
treated hearts and from 92 6 2 mm Hg to 68 6 3
mm Hg (74% of preischemic level) in the FDP-
treated hearts. On further reperfusion with Krebs
buffer (without FDP) in both groups, there was
significantly better recovery of developed pressure
in the FDP-treated hearts (91% of preischemic
level) by 60 minutes of reperfusion (Fig. 4, a)
compared with the control untreated hearts. Dia-
stolic pressure was significantly elevated by 30 min-
utes of reperfusion in control hearts (from 7.8 6 0.5
mm Hg before ischemia to 13 6 2 mm Hg) without
further recovery by 60 minutes of reperfusion. In
contrast, in the FDP-treated hearts, diastolic pres-
sure remained at preischemic values during the
entire reperfusion period (Fig. 4, b).
To determine whether the beneficial effects of
FDP on reperfusion were due to its ability to bind
calcium and thus lower extracellular calcium con-
tent during early reperfusion, we performed the
following experiments. In a separate group of
hearts (n 5 4 per group), the same experiment as
described above was repeated, but this time ion-
ized calcium was normalized (1.2 mmol/L) in the
perfusate containing FDP (5 mmol/L). Hearts
were reperfused with Krebs buffer containing
FDP with or without calcium during the first 30
minutes of reperfusion followed by an additional
30 minutes of perfusion with Krebs buffer (with-
out FDP). Diastolic and developed pressure was
measured after reperfusion and compared with
pressures in a group receiving FDP without addi-
tional calcium and a control group receiving only
Krebs buffer. Recovery of developed pressure was
significantly better in the FDP-treated hearts than
Fig. 5. MVO2 (a), glucose uptake (b), and lactate release (c) in hearts after 30 minutes of 37° C ischemia
and 45 minutes of reperfusion. In one group, a 5 mmol/L concentration of FDP was added to the Krebs
buffer for the initial 30 minutes of reperfusion followed by 15 minutes with Krebs buffer alone (wash). In
a second (control) group, hearts were reperfused with Krebs buffer alone. Lactate release represents the
total lactate released into the coronary effluent during the indicated reperfusion period. All values are
mean 6 standard error. *p , 0.05 compared with control hearts; n 5 6 per group.
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in controls, with no difference between the FDP
plus calcium group versus the FDP without added
calcium group (Table I). Similarly, diastolic pres-
sure was significantly lower in both FDP-treated
groups than in control hearts, with no difference
between the two FDP-treated groups.
Substrate use. Fig. 5, a, depicts MVO2 before
ischemia and during reperfusion. In both control
and FDP-treated hearts, MVO2 was significantly
lower than preischemic levels during the first 10
minutes of reperfusion. In FDP-treated hearts, how-
ever, MVO2 recovered to preischemic levels by the
end of the FDP infusion (30 minutes of reperfu-
sion), and MVO2 was maintained at those levels
during the subsequent 15 minutes of plain Krebs
perfusion. In control hearts, MVO2 remained de-
pressed during the entire reperfusion period. Glu-
cose extraction was also maintained at preischemic
levels in the FDP-treated hearts with a decline on
FDP withdrawal. The higher glucose uptake on
reperfusion in the FDP-treated hearts was associ-
ated with significantly lower lactate release from
these hearts, indicating increased oxidative metabo-
lism compared with control untreated hearts (Fig. 5,
b and c).
Myocardial high-energy phosphates. PCr levels
rapidly fell after the onset of ischemia followed by a
more gradual decline in ATP levels during ischemia
(Fig. 6 and Table II). On reperfusion there was a
rapid recovery in PCr with a typical overshoot seen
in the first 5 minutes of reperfusion. In FDP-treated
hearts, supernormal PCr levels were maintained
during the FDP infusion, with gradual return to
preischemic levels during the washout period. In
control hearts, after the initial overshoot, PCr levels
fell to levels slightly below preischemic values by the
end of the 45-minute reperfusion period. Similar to
the FDP-treated nonischemic hearts, postischemic
FDP-treated hearts had higher levels of intracellular
Pi during the FDP infusion. However, Pi concentra-
tion recovered to control levels after FDP with-
drawal (Table II).
Fig. 6. Phosphocreatine concentration (expressed as percent of preischemic value) during ischemia and 45
minutes of reperfusion. In one group, a 5 mmol/L concentration of FDP was added to the Krebs buffer for
the initial 30 minutes of reperfusion followed by 15 minutes of perfusion with Krebs buffer alone (wash).
In a second (control) group, hearts were reperfused with Krebs buffer alone. All values are mean 6
standard error. *p , 0.05 compared with control hearts; n 5 6 per group).
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Discussion
This study demonstrates that FDP has important
dose-dependent effects on the crystalloid-perfused
nonischemic heart, including increased glucose up-
take and high-energy phosphate levels. Exogenous
FDP also caused a fall in developed pressure, owing
in part to its ability to bind free calcium and in part
to elevated intracellular Pi levels.8 In the postisch-
emic heart, FDP given during early reperfusion
leads to significantly improved recovery of systolic
and diastolic function in association with increased
glucose uptake and PCr levels.
FDP is an intermediate in the glycolytic pathway,
which is formed by the phosphorylation of fruc-
tose-6 phosphate and is cleaved into dihydroxy-
acetone phosphate and glyceraldehyde 3-phosphate
by aldolase. Conversely, FDP can be converted to
fructose-6 phosphate by hydrolysis of the phosphate
ester at C-1 during gluconeogenesis. Under physio-
logic conditions, FDP levels in the cytosol are
maintained in the micromolar range. Our finding
that a high extracellular FDP concentration was
associated with increased glucose uptake in both the
nonischemic and postischemic hearts indicates that
one of the effects of exogenous FDP is to accelerate
glycolytic flux in the cell. There are two proposed
mechanisms to explain the increased glucose uptake
seen with exogenous FDP. One explanation is that
FDP can enter the cytosol and provide a direct
substrate for the glycolytic pathway entering at an
energetically favorable level where ATP-dependent
phosphorylation is not required. The second expla-
nation is that FDP acts to stimulate glycolysis by
increasing glycolytic or Krebs cycle enzyme activity
leading to increased glycolytic flux and oxidative
metabolism.3, 7, 9-11
Phosphorylation of sugars has been generally
regarded as a mechanism for trapping these sub-
strates inside cells owing to the low permeability
through biologic membranes of the sugar phosphate
ester. Even Pi translocation across the plasma mem-
brane has been shown to be slow.9 However, since
the concentration of free FDP in the cytosol is only
1.2 mmol/L,6 an infusion of FDP in the millimolar
concentration range results in a more than thou-
sand-fold gradient across the plasma membrane.
The fact that, in our study, the effects of FDP in the
heart were dose dependent and that total intracel-
lular phosphates were increased during FDP infu-
sion further supports the contention that FDP can
cross the sarcolemmal membrane under these ex-
perimental conditions. Other investigators studying
the effects of exogenous FDP in hypoxic smooth
muscle cells have provided direct evidence that FDP
can cross the cell membrane and serve as a meta-
bolic substrate.3 Using 13C-labeled FDP, they dem-
onstrated that FDP enters the cell and leads to the
production of 13C-lactate during hypoxia in a dose-
dependent manner. The mechanism of entry of FDP
into the cells is not known. However, owing to
structural similarities between FDP and membrane
phospholipids, investigators have suggested that
FDP can interact with membrane proteins to create
polar discontinuities that may permit FDP to per-
meate the cell membrane.10
The exact effects of exogenous FDP on glucose
metabolism inside the cell are not completely clear.
Hassinen and associates7 have suggested that exter-
nal FDP is not used as a glycolytic substrate in the
heart, since they found that maximal protection
from anoxic damage was achieved with a 6 mmol/L
concentration of FDP only in the presence of glu-
cose, suggesting a pharmacologic effect of FDP on
glycolytic enzyme activity. Similar results have been
shown in astrocytes subjected to hypoxia.11 Glyco-
lytic activity is regulated not only by substrate avail-
ability but also by enzyme activity, particularly hex-
okinase, phosphofructokinase, and pyruvate kinase.
Hexokinase, phosphofructokinase, and pyruvate ki-
nase are believed to have regulatory as well as
catalytic roles in glycolysis.12 FDP, a product of the
early steps in glycolysis, activates pyruvate kinase to
enable it to keep pace with the oncoming high flux
of intermediates. Exogenous FDP may therefore be
able to activate pyruvate kinase and cause acceler-
ation of glycolysis.13 Alternatively, reversal of the
glycolytic steps producing fructose-6-phosphate may
lead to fructose 2,6-bisphosphate generation using
the enzyme fructose 1,6-bisphosphatase.2 Fructose
Table II. Effect of FDP on Pi and ATP in the
ischemia/reperfusion model
Pre-
ischemia
(%)
End-
ischemia
30 min
reperfusion
(6 5 mmol/L
FDP)
15 min
wash
(2FDP)
Pi
Control 100 854 6 80 223 6 62 282 6 77
FDP (5 mmol/L) 100 734 6 103 386 6 82* 288 6 63
ATP
Control 100 65 6 5 72 6 4 59 6 4
FDP (5 mmol/L) 100 56 6 5 78 6 5 66 6 4
Values are expressed as percent of preischemic values.
*p , 0.05 versus control; n 5 6 per group.
The Journal of Thoracic and
Cardiovascular Surgery
August 1998
3 4 2 Takeuchi et al.
2,6-bisphosphate is a known potent activator of
phosphofructokinase and serves to stimulate glyco-
lytic flux.13, 14
The mechanism by which exogenous FDP de-
creases contractile force in the nonischemic heart is
probably multifactorial. Our observation that a 5
mmol/L concentration of FDP is able to lower free
Ca21 concentration by 32% in standard Krebs buffer
and that by normalizing ionized calcium most of the
contractile function returns indicates that this is the
major mechanism of FDP effects on myocardial
contractility. Hassinen and associates7 showed a
similar effect of FDP on contractile function in an
isolated rat heart model and also ascribed the effects
to calcium chelation. Although the negative inotro-
pic effects of FDP on the normal nonischemic heart
may seem undesirable, during early reperfusion the
calcium chelating effects of FDP may provide some
protection. Calcium overload during reperfusion is a
widely known mechanism of injury to the heart after
severe reversible ischemia, and the ability of FDP to
chelate calcium may explain some of the beneficial
effects we observed in our study. Whether FDP
prevents calcium overload simply by chelating extra-
cellular calcium or whether it is capable of entering
the cell to lower calcium we cannot determine in this
study, because we did not measure intracellular
calcium levels. However, in the experiments in
which hearts were reperfused with FDP and the
ionized calcium was normalized (1.2 mmol/L), we
were unable to detect any significant difference in
recovery of contractile function compared with the
hearts receiving FDP alone. These results indicate
that, in our model of ischemia/reperfusion, the
calcium-chelating activity of FDP is not a major
mechanism for the improved recovery of postisch-
emic contractile function.
Regardless of the exact mechanism, however, our
study demonstrates that exogenous FDP, when
given during early reperfusion, increases glucose
uptake, oxidative metabolism, and PCr levels lead-
ing to significantly improved recovery of contractile
function in the postischemic crystalloid-perfused
rabbit heart.
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